Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SKIN vs MRVI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SKIN Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 5–5 Matrix Metrics)

SKIN Overall Winner 6-Pillar Tally: SKIN 4 – 2 MRVI Matrix Metrics: SKIN 5 – 5 MRVI

As of Nov 16, 2026, The Beauty Health Company (SKIN) is the stronger overall head-to-head candidate over Maravai LifeSciences Holdings, Inc. (MRVI) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). SKIN carries a Unified Composite Score of 34.1/100 (SELL) at $15.05 (106.4x Forward P/E, 2.4% operating margin), whereas MRVI carries 52.0/100 (HOLD) at $7.40 (N/M Forward P/E, -24.2% operating margin).

  • Composite vs. Pillar Nuance: While MRVI currently prints a higher short-term Unified Composite Score (52.0/100 HOLD vs. SKIN 34.1/100 SELL), SKIN captures the overall institutional head-to-head verdict (5–5 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (2.4% vs. -24.2% operating margin) and revenue trajectory (-2.1% vs. +10.1% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SKIN vs MRVI
SKIN NASDAQ Head-to-Head Winner
The Beauty Health Company Class A Common Stock
Surgical & Medical Instruments & Apparatus
$15.05
-7.73% 1D
Market Cap $106.3M
TTM Revenue $289M
Forward P/E 106.4x
Beta / 30D Vol -14.22β · 192% Vol
Unified Composite Score
34.1 / 100 SELL
Tech 50.0 Fund 34.0 Flow 67.0 Mom 46.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (315.4% over 20 days), RSI 70
RSI-14: 69.8 · SMA20: $12.52 · SMA50: $6.25
MRVI NASDAQ
Maravai LifeSciences Holdings, Inc. Class A Common Stock
Pharmaceutical Preparations
$7.40
-1.86% 1D
Market Cap $2.0B
TTM Revenue $213M
Forward P/E N/M
Beta / 30D Vol 1.61β · 83% Vol
Unified Composite Score
52.0 / 100 HOLD
Tech 37.0 Fund 53.0 Flow 67.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 49
RSI-14: 49.1 · SMA20: $7.64 · SMA50: $7.40

6-Pillar Scorecard Institutional Category Breakdown (SKIN 4 – 2 MRVI)

Columns: Metric · SKIN · MRVI
1. Valuation Multiples SKIN
Forward P/E 106.4x N/M
Trailing P/E 106.4x N/M
PEG Ratio 0.93x N/M
EV / Revenue 0.9x 9.7x
2. Growth & Scale MRVI
Revenue Growth (YoY) -2.1% +10.1%
Earnings Growth (YoY) +0.0% -32.7%
TTM Revenue (USD) $289M $213M
Market Cap $106.3M $2.0B
3. Profitability & Quality SKIN
Gross Margin 67.2% 39.9%
Operating Margin 2.4% -24.2%
Net Profit Margin -6.3% -30.8%
Return on Equity (ROE) -30.1% -29.8%
4. Balance Sheet & Cash Flow SKIN
Cash Generation (TTM) $17M -$13M
Cash Flow Margin 5.8% -5.9%
Net Cash / Leverage $161M Net Debt (6.61x D/E) $103M Net Debt (0.90x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MRVI
Options Structure Phase UNCLASSIFIED BREAKOUT
Current IV / %ile 517.4% (100th %ile) 167.3% (35th %ile)
Put/Call OI Skew N/A 0.01x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat SKIN
OpEx & R&D Intensity 64.8% of Rev ($187M) 64.1% of Rev ($137M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Household & Personal Products Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SKIN (5) vs MRVI (5)
Institutional Metric SKIN MRVI Criterion Row Edge
Market Capitalization
Scale
$106.3M $2.0B Larger Scale MRVI
Trailing P/E Ratio
Valuation
106.4x N/M Lower Multiple SKIN
Forward P/E Ratio
Valuation
106.4x N/M Lower Multiple SKIN
Revenue Growth (YoY)
Growth
-2.1% +10.1% Higher Growth MRVI
Operating Margin (TTM)
Profitability
2.4% -24.2% Higher Margin SKIN
Net Profit Margin
Profitability
-6.3% -30.8% Higher Margin SKIN
Return on Equity (ROE)
Capital Efficiency
-30.1% -29.8% Higher ROE MRVI
52-Week Range Position
Momentum
83% ($0–$18) 70% ($3–$9) Stronger Trend SKIN
Beta / 30D Volatility
Risk Regime
-14.22β · 192% Vol 1.61β · 83% Vol Lower Realized Risk MRVI
Unified Institutional Score
Composite Signal
34.1 / 100 (SELL) 52.0 / 100 (HOLD) Higher Composite MRVI
Trailing 12M Revenue (USD)
Operating Scale
$289M $213M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
67.2% 39.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.93x PEG · 0.9x EV/Rev N/M PEG · 9.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$17M ($161M Net Debt (6.61x D/E)) -$13M ($103M Net Debt (0.90x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SKIN +33.54 pp
SKIN: +42.52% · MRVI: +8.98%
3M Horizon SKIN +2379.41 pp
SKIN: +2408.33% · MRVI: +28.92%
6M Horizon SKIN +2303.77 pp
SKIN: +2385.14% · MRVI: +81.37%
1Y Horizon SKIN +930.0 pp
SKIN: +1057.69% · MRVI: +127.69%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SKIN Revenue MRVI Revenue SKIN Op. Margin MRVI Op. Margin Margin Leader
FY2019 $170M $140M 8.1% 16.8% MRVI
FY2020 $120M $280M -14.4% 42.2% MRVI
FY2021 $260M $800M -15.4% 69.4% MRVI
FY2022 $370M $880M -7.1% 65.0% MRVI
FY2023 $400M $290M -32.9% -11.0% MRVI
FY2024 $330M $260M -20.3% -90.9% SKIN
FY2025 $300M $190M -6.9% -115.9% SKIN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SKIN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 517.4%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact SKIN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MRVI BREAKOUT
98d in phase · OBV DISTRIBUTION
Current IV 167.3%
IV Percentile 35th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact MRVI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SKIN Moat Profile Cyclical / Execution-Driven Positioning
Household & Personal Products Operator
Competes within the Household & Personal Products value chain with $106.3M market capitalization and 2.4% operating margin.
OpEx & R&D Reinvestment 64.8% of Rev ($187M)
90D Engineering Disclosures 0 Published
MRVI Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.0B market capitalization and -24.2% operating margin.
OpEx & R&D Reinvestment 64.1% of Rev ($137M)
90D Engineering Disclosures 0 Published

Investor FAQ SKIN vs MRVI Key Questions & Quantitative Answers

As of Nov 16, 2026, The Beauty Health Company (SKIN) is the stronger overall head-to-head candidate over Maravai LifeSciences Holdings, Inc. (MRVI) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). SKIN carries a Unified Composite Score of 34.1/100 (SELL) at $15.05 (106.4x Forward P/E, 2.4% operating margin), whereas MRVI carries 52.0/100 (HOLD) at $7.40 (N/M Forward P/E, -24.2% operating margin). Composite vs. Pillar Nuance: While MRVI currently prints a higher short-term Unified Composite Score (52.0/100 HOLD vs. SKIN 34.1/100 SELL), SKIN captures the overall institutional head-to-head verdict (5–5 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (2.4% vs. -24.2% operating margin) and revenue trajectory (-2.1% vs. +10.1% YoY).

MRVI leads the Growth & Scale pillar: SKIN posts -2.1% YoY revenue growth and +0.0% YoY earnings growth on $289M TTM revenue (67.2% gross margin, 2.4% operating margin), compared with MRVI at +10.1% YoY revenue growth and -32.7% YoY earnings growth on $213M TTM revenue (39.9% gross margin, -24.2% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), SKIN cumulative revenue shifted +76.5% while MRVI shifted +35.7%. In operating R&D and SG&A reinvestment, SKIN deploys 64.8% of Rev ($187M) (0 90-day corporate R&D disclosures) versus 64.1% of Rev ($137M) (0 disclosures) for MRVI.

SKIN screens cheaper on headline valuation multiples. SKIN trades at 106.4x Forward P/E, 106.4x Trailing P/E, 0.93x PEG, and 0.9x EV/Revenue (5.8% FCF margin), whereas MRVI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.7x EV/Revenue (-5.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SKIN (-30.1% ROE) versus MRVI (-29.8% ROE) capital efficiency.

In options market volatility and institutional positioning, SKIN carries 517.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-14.22β · 192% Vol realized risk). By comparison, MRVI carries 167.3% implied volatility (35th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKOUT options structure phase (1.61β · 83% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

The Beauty Health Company Class A Common Stock (SKIN) Research Suite

Maravai LifeSciences Holdings, Inc. Class A Common Stock (MRVI) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.